Currently, hemoglobin (Hb)-based oxygen carriers (HBOCs) are leading candidates as red blood cell substitutes. In addition, HBOCs are also potential oxygen therapeutics for treatment of patients with critical ischemic conditions due to atherosclerosis, diabetes and other conditions. This book will provide readers a comprehensive review of topics involved in the HBOC development. It focusses on current products and clinical applications as well as on emerging technologies and future prospects.

This book functions as a comprehensive and authoritative reference book in blood transfusion and blood substitutes. It is a collection of the latest developments and the newest investigations, and individual chapters are written by world experts in the arena. The book begins with a historical review on the practice of transfusions as well as the components and physiology of blood. The following chapters cover various topics, including platelet substitutes, hemoglobin-based oxygen carriers, perfluorocarbon based oxygen carriers, and safety issues related to artificial hemoglobin. All chapters provide a bulleted highlights list to facilitate readers in mastering the main points of each individual chapter. Blood Substitutes and Oxygen Biotherapeutics is an invaluable reference book for perioperative care providers, hematologists, anesthesiologists, surgeons, obstetricians and gynecologists.

This comprehensive book is written to inform and improve outcomes of patients in need of blood management during surgical procedures. Information is presented in an accessible format, allowing for immediate use in clinical practice. Beginning with an overview of the history of blood transfusions, early chapters present the foundational information needed to comprehend information in later chapters. Nuanced procedures, drugs, and techniques are covered, including new biologicals to assist clotting and blood substitutes. Further discussions focus on potential complications seen in blood transfusions, such as diseases of the coagulation system, pathogen transmissions, and acute lung injuries. Chapters also examine the complexities of treating specific demographics, of which include the geriatric patient and patients suffering from substance abuse. Essentials of Blood Product Management in Anesthesia Practice is an invaluable guide for anesthesiologists, surgeons, trauma physicians, and solid organ transplant providers.

Artificial Cells are not to reproduce biological cells but to prepare an artificial system for possible uses in medicine and other areas. Many of the ideas on artificial cells are being extensively applied and extended by researchers worldwide, resulting in rapid and exciting progress and discoveries. Different configurations include using emulsion methods and microfluidizers to form microscopic or nano dimension cells called artificial cells, synthetic cells, microcapsules, nanocapsules, liposomes, microparticles, nanoparticles, polymersomes, etc. Macro dimensions artificial cells are used for bioencapsulated cells. Soluble nanobiotherapeutics can be formed by crosslinking proteins and enzymes or by PEG conjugation. The principle of artificial cell has now evolved into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, replicating synthetic cells, cell encapsulation, biosorbent/immunosorbent hemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, COVID_19 vaccine, COVID_19 therapy, nanobiotechnology, nanotechnology and other areas.

This volume of the Keio University International Symposia for Life Sciences and Medicine contains the proceedings of the 13th symposium held under the sponsorship of the Keio University Medical Science Fund. The fund was est- lished by the generous donation of the late Dr. Mitsunada Sakaguchi. The Keio University International Symposia for Life Sciences and Medicine constitute one of the core activities sponsored by the fund,of which the objective is to contribute to the international community by developing human resources, promoting scienti?c knowledge, and encouraging mutual exchange. Each year, the Committee of the International Symposia for Life Sciences and Medicine selects the most signi?cant symposium topics from applications received from the Keio medical community. The publication of the proce- ings is intended to publicize and distribute the information arising from the lively discussions of the most exciting and current issues presented during the symposium. On behalf of the Committee, I am most grateful to the late Dr. Sakaguchi, who made the series of symposia possible. We are also grateful to the prominent speakers for their contribution to this volume. In addition, we would like to acknowledge the ef?cient organizational work performed by the members of the program committee and the staff of the fund. Naoki Aikawa, M. D. , D. M. Sc. , F. A. C. S.

This definitive volume will provide the reader with up to date information and the most recent science of the fast-evolving area of nanobiotherapeutic-based blood substitutes. Long studied, there are recent updates that make their use in patients more promising, and with one product approved for human use, many more in the pipeline. These include 2nd generations and even third generation ones, the later with enhancement of red blood cell functions. In addition, there are carefully written and referenced updates on the recent history and products in the field, complete with pathophysiologic and pharmacologic studies to validate and verify the efficacy and safety of many of these new products.

A critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in academia and industry, to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are "cured" by available treatments. In 5 sections, the proposed volume will explore historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the recent bench-side research.

This book presents a comprehensive overview of medical and pharmaceutical applications of human serum albumin (HSA), with updates on structural aspects of albumin from the perspectives of X-ray crystallography and NMR, endogenous and exogenous ligand binding of albumin in various pathological conditions, and genetic variants and their phenotypes. Rapid progress and development of its applications have resulted in outstanding results for which albumin has clearly been proven to be a robust biomaterial. Contributions from leading international experts in this field show how HSA is applied to diagnosis, therapy, drugs, and treatment, with a comprehensive introduction of HSA. This volume will appeal to scientists in pharmaceutical and medical research including pharmaceutical chemists, pharmacokineticists, toxicologists, and biochemists not only in academia but also in industry. Readers can effectively acquire the most recent knowledge of applications of HSA and its impact on human health in a single volume.

This book provides a comprehensive overview of damage control resuscitation (DCR), an evidence-based approach to the resuscitation of patients with severe life-threatening hemorrhage (LTH). It focuses on both civilian and military applications as DCR is utilized in civilian trauma situations as well as combat casualty care settings. The book covers the history of fluid resuscitation for bleeding, epidemiology of severe traumatic injuries, prediction of life-threatening hemorrhage, pathophysiology and diagnosis of blood failure, and permissive hypotension. Chapters provide in-depth detail on hemostatic resuscitation principles, dried plasma, dried platelet surrogates, and recent developments in frozen red blood cells and oxygen carriers. The book also discusses how DCR principles can be used in a variety of situations such as when there are large numbers of patients with hemorrhagic lesions, non-trauma scenarios, and on distinct populations such as children. Finally, it concludes with a discussion of training and education methods for the implementation of DCR and remote DCR principles as well as learning healthcare system principles to facilitate the implementation of DCR and ultimately improve outcomes for patients with life-threatening hemorrhage. Damage Control Resuscitation: Identification and Treatment of Life-Threatening Hemorrhage is an essential resource for physicians and related professionals, residents, nurses and medical students in emergency medicine, anesthesia, surgery, and critical care, as well as civilian and military EMS providers.